Physiologically Based Pharmacokinetic Modeling of a Homologous Series of Barbiturates in the Rat: A Sensitivity Analysis

被引:0
|
作者
Ivan A. Nestorov
Leon J. Aarons
Malcolm Rowland
机构
[1] Central Laboratory of Biomedical Engineering,Department of Pharmacy
[2] University of Manchester,undefined
关键词
sensitivity analysis; simulation; physiologically based pharmacokinetic model; matrix perturbation analysis; compartmental system;
D O I
暂无
中图分类号
学科分类号
摘要
Sensitivity analysis studies the effects of the inherent variability and uncertainty in model parameters on the model outputs and may be a useful tool at all stages of the pharmacokinetic modeling process. The present study examined the sensitivity of a whole-body physiologically based pharmacokinetic (PBPK) model for the distribution kinetics of nine 5-n-alkyl-5-ethyl barbituric acids in arterial blood and 14 tissues (lung, liver, kidney, stomach, pancreas, spleen, gut, muscle, adipose, skin, bone, heart, brain, testes) after iv bolus administration to rats. The aims were to obtain new insights into the model used, to rank the model parameters involved according to their impact on the model outputs and to study the changes in the sensitivity induced by the increase in the lipophilicity of the homologues on ascending the series. Two approaches for sensitivity analysis have been implemented. The first, based on the Matrix Perturbation Theory, uses a sensitivity index defined as the normalized sensitivity of the 2-norm of the model compartmental matrix to perturbations in its entries. The second approach uses the traditional definition of the normalized sensitivity function as the relative change in a model state (a tissue concentration) corresponding to a relative change in a model parameter. Autosensitivity has been defined as sensitivity of a state to any of its parameters; cross-sensitivity as the sensitivity of a state to any other states' parameters. Using the two approaches, the sensitivity of representative tissue concentrations (lung, liver, kidney, stomach, gut, adipose, heart, and brain) to the following model parameters: tissue-to-unbound plasma partition coefficients, tissue blood flows, unbound renal and intrinsic hepatic clearance, permeability surface area product of the brain, have been analyzed. Both the tissues and the parameters were ranked according to their sensitivity and impact. The following general conclusions were drawn: (i) the overall sensitivity of the system to all parameters involved is small due to the weak connectivity of the system structure; (ii) the time course of both the auto- and cross-sensitivity functions for all tissues depends on the dynamics of the tissues themselves, e.g., the higher the perfusion of a tissue, the higher are both its cross-sensitivity to other tissues' parameters and the cross-sensitivities of other tissues to its parameters; and (iii) with a few exceptions, there is not a marked influence of the lipophilicity of the homologues on either the pattern or the values of the sensitivity functions. The estimates of the sensitivity and the subsequent tissue and parameter rankings may be extended to other drugs, sharing the same common structure of the whole body PBPK model, and having similar model parameters. Results show also that the computationally simple Matrix Perturbation Analysis should be used only when an initial idea about the sensitivity of a system is required. If comprehensive information regarding the sensitivity is needed, the numerically expensive Direct Sensitivity Analysis should be used.
引用
收藏
页码:413 / 447
页数:34
相关论文
共 50 条
  • [41] Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats
    Krishnan, Kannan
    Crouse, Lee C. B.
    Bazar, Matthew A.
    Major, Michael A.
    Reddy, Gunda
    JOURNAL OF APPLIED TOXICOLOGY, 2009, 29 (07) : 629 - 637
  • [42] The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
    Huang, S-M
    Rowland, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (03) : 542 - 549
  • [43] Physiologically Based Pharmacokinetic Modeling of Imatinib Using Simcyp
    Lu, Deshun
    Kunapareddy, Kundan
    Simpson, Edward
    Dave, Nimita
    Quinney, Sara
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S93 - S93
  • [44] Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children
    Elizabeth J. Thompson
    Huali Wu
    Anil Maharaj
    Andrea N. Edginton
    Stephen J. Balevic
    Marjan Cobbaert
    Anthony P. Cunningham
    Christoph P. Hornik
    Michael Cohen-Wolkowiez
    Clinical Pharmacokinetics, 2019, 58 : 887 - 898
  • [45] Physiologically based pharmacokinetic modeling in obesity: applications and challenges
    Yang, Ruwei
    Ding, Qin
    Ding, Junjie
    Zhu, Liyong
    Pei, Qi
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (08) : 805 - 816
  • [46] Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics
    Yu, Yanke
    DuBois, Steven G.
    Wetmore, Cynthia
    Khosravan, Reza
    AAPS JOURNAL, 2020, 22 (02):
  • [47] Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics
    Yanke Yu
    Steven G. DuBois
    Cynthia Wetmore
    Reza Khosravan
    The AAPS Journal, 22
  • [48] Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay!
    Rostami-Hodjegan, Amin
    Tamai, Ikumi
    Pang, K. Sandy
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (02) : 47 - 50
  • [49] Physiologically based pharmacokinetic (PBPK) modeling in the age of AI
    Morozov, V.
    Dzierlenga, M.
    Kapraun, D.
    Lin, Y.
    Watford, S.
    Shapiro, A.
    Schlosser, P.
    Zurlinden, T.
    FEBS OPEN BIO, 2024, 14 : 438 - 438
  • [50] Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations
    Maxime Le Merdy
    Jessica Spires
    Viera Lukacova
    Ming-Liang Tan
    Andrew Babiskin
    Xiaoming Xu
    Liang Zhao
    Michael B. Bolger
    Pharmaceutical Research, 2020, 37